{"id":19291,"date":"2023-01-16T18:39:33","date_gmt":"2023-01-16T17:39:33","guid":{"rendered":"https:\/\/staging.seat11a.com\/?post_type=video_skrn&p=19291"},"modified":"2023-10-10T18:05:52","modified_gmt":"2023-10-10T17:05:52","slug":"brain-biotech-ag-financial-results-fy-2022","status":"publish","type":"video_skrn","link":"https:\/\/seat11a.com\/company\/brain-biotech-ag-financial-results-fy-2022\/","title":{"rendered":"BRAIN Biotech AG Financial Results FY 2021 \/ 22 | Exploring Growth, Challenges, and Future Prospects with CFO"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tBRAIN Biotech AG FY 2021\/22: Key Takeaways\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Revenue Growth in BRAIN Biotech AG<\/h2>

BRAIN Biotech AG, a leading provider of biologization solutions for industries, has reported strong revenue growth in both segments, contributing to a total group revenue increase of 35% and an organic increase of 19% in the first quarter the fiscal year 2022\/23.<\/p>

\u00a0<\/p>

BioIndustrial and BioScience Segment Performance<\/h3>

The BioIndustrial segment saw revenue growth of 43.5%, and the BioScience segment’s revenue increased by 10.5% on an organic basis. The company’s cash on hand also improved by \u20ac2.4 million to \u20ac10.8 million, including the proceeds from the disposal of L.A. Schmitt GmbH.<\/p>

\u00a0<\/p>

Profitability and Investments<\/h3>

Despite higher personnel and project investments, BRAIN Biotech’s adjusted EBITDA remained profitable.<\/p>

\u00a0<\/p>

Quarterly Highlights and Collaborations<\/h3>

Important events for the quarter included MP Beteiligungs-GmbH expanding its shareholding to approximately 45% and the company reaching project milestones in its collaboration with rare sugars expert Bonumose.<\/p>

\u00a0<\/p>

CFO Insights into Fiscal Year Prospects<\/h3>

Michael Schneiders, CFO, expressed optimism for the rest of the fiscal year, noting the company’s solid growth as a foundation for handling inflationary costs.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Chapters<\/h3>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t